Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Share-based Compensation: 2018-2024

Historic Share-based Compensation for Eton Pharmaceuticals (ETON) over the last 7 years, with Dec 2024 value amounting to $3.2 million.

  • Eton Pharmaceuticals' Share-based Compensation fell 54.18% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 7.84%. This contributed to the annual value of $3.2 million for FY2024, which is 0.89% up from last year.
  • Per Eton Pharmaceuticals' latest filing, its Share-based Compensation stood at $3.2 million for FY2024, which was up 0.89% from $3.1 million recorded in FY2023.
  • In the past 5 years, Eton Pharmaceuticals' Share-based Compensation registered a high of $4.2 million during FY2022, and its lowest value of $2.6 million during FY2020.
  • Over the past 3 years, Eton Pharmaceuticals' median Share-based Compensation value was $3.2 million (recorded in 2024), while the average stood at $3.5 million.
  • In the last 5 years, Eton Pharmaceuticals' Share-based Compensation spiked by 36.44% in 2020 and then decreased by 25.63% in 2023.
  • Yearly analysis of 5 years shows Eton Pharmaceuticals' Share-based Compensation stood at $2.6 million in 2020, then skyrocketed by 31.25% to $3.4 million in 2021, then climbed by 24.76% to $4.2 million in 2022, then dropped by 25.63% to $3.1 million in 2023, then increased by 0.89% to $3.2 million in 2024.